Metformin: a case of divide and conquerMore about Open Access at the Crick
Metformin is a widely prescribed anti-diabetic drug and its use is associated with lower cancer incidence. The mechanisms by which metformin attenuates tumorigenesis are not clearly understood. In a paper published in Proceedings of the National Academy of Sciences of the United States of America, Hirsch and colleagues show that metformin interferes with a signaling pathway, mediated by the transcription factor NF-κB, which drives cell transformation and is required for the maintenance of cancer stem cells.
Journal Breast Cancer Research
Issue number 2
Full text links
Publisher website (DOI) 10.1186/bcr3387
Europe PubMed Central 23510106
Type of publication